Intrexon To Buy Rest Of Exemplar Genetics

(RTTNews) - Intrexon Corp. (XON) sid Monday that it has launched a tender offer to acquire the remaining stake in Exemplar Genetics.

Utilizing its proprietary technologies in animal genetics, Exemplar has developed a broad pipeline of transgenic swine models for research and development of heart disease, cancer, cystic fibrosis, cardiac arrhythmia, neuromuscular and neurodegenerative disorders. ExeGen LDLR-/-&+/- is the company's most advanced porcine model designed to empower superior drug and device discovery in the area of cardiac disease.

Exemplar Genetics will be presenting its miniature swine preclinical oncology model expressing a cancer mutation in the TP53 gene at the Molecular Med Tri-Con Conference held in San Francisco, February 16-18. Data suggests the model is representative of the human condition in exhibiting lymphomas as well as osteogenic tumors and may be useful in facilitating development of approaches for detection and treatment of cancers.